TG Therapeutics, Inc. (TGTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 8.16B USD. 52-week range 26.76 to 59.30 USD. Trailing P/E 19.4. Data as of 2026-10-09.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The ...